PIK3CA mutations attenuate the antiproliferative effects of a HER2 inhibitor and an AKT inhibitor enhances the antiproliferative activity of a HER2 inhibitor in PIK3CA-mut HER2+ breast cancer cell lines. The gene discussed is PIK3CA; the disease is breast carcinoma.